Biotech Values

[poorgradstudent]

My intent is not to question whether enzalutamide is active, or better than abi or cabo, etc. It is to quantify the effect of later availability of cabo & abi to the HR and then extend that info to the SYNERGY trial as, similar to the AFFIRM trial, abi & enzalutamide got approved during the SYNERGY trial. If OGX-011 has even a minor OS advantage, would these approvals extend the HR of the SYNERGY trial in favor of OGX-011?

Off-hand I would think that the effect of the subsequent therapy would have to be big, wouldn't it? I say this because you likely have only a subset of those progressing subsequently moving onto the therapies that you're listing. If both arms move to subsequent therapies in same numbers, I would think it would do more to dilute the post-treatment effect than to accentuate it.